此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

IMST用于降低痴呆症风险

2026年11月2日 更新者：Julia Sheffler、Florida State University

针对老年人的吸气肌力量训练（IMST）以降低痴呆风险的随机对照先导试验

Using a 2-arm, RCT approach, the primary goal of the study is to evaluate the feasibility and preliminary efficacy of Inspiratory Muscle Strength Training (IMST) as a non-pharmacologic intervention to reduce cardiovascular and cognitive risks in older adults. Next, investigators will examine secondary effects of IMST on mood, sleep quality, systemic inflammation, and physical/motor function. Finally, investigators will assess participant adherence and acceptability ratings of using an 8-week home-based IMST protocol in a diverse older adult sample.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

This is a 2-arm randomized pilot trial (N=30), including adults aged 60-80 years of age with cardiovascular risks for dementia. Participants will complete assessments prior to beginning the study, each week during the intervention, and at the conclusion of the 8-week intervention. Participants in the experimental group will complete daily high-resistance IMST training (e.g., 75% maximal inspiratory pressure), and participants in the sham condition will complete IMST training at 15% maximal inspiratory pressure. Investigators hypothesize the following: Hypothesis 1: Participants in the high-resistance IMST group will show greater reductions in systolic blood pressure and other vascular health indicators compared to those in the sham IMST group after 8 weeks.

Hypothesis 2: Participants in the high-resistance IMST group will demonstrate greater improvements in executive cognitive function than those in the sham group.

Hypothesis 3: IMST will lead to secondary improvements in mood (reduced depression and anxiety symptoms), better sleep quality (as measured by self-report and actigraphy), and improved physical function (e.g., grip strength, gait speed).

Hypothesis 4: The IMST protocol will be feasible and acceptable, with at least 80% adherence to prescribed training sessions over the 8-week period.

研究类型

介入性

注册 (估计的)

30

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • Florida
      • Tallahassee、Florida、美国、32301

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

60年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Ages 60-80
  • Converted telephone MoCA total score≥18
  • Presence of at least one dementia risk factor (e.g., MCI or subjective cognitive decline, hypertension [SBP >130 mmHg or on medication], sedentary lifestyle [<150 min/week], family history of dementia or self-reported APOE ε4 carrier, or mild sleep-disordered breathing; CAIDE total score [>5]
  • Capable of independently completing or requiring minimal assistance with inspiratory muscle strength training (IMST)
  • Willing to adhere to the IMST protocol (approximately 5-10 minutes per day for 8 weeks)
  • Optional inclusion of inspiratory muscle weakness (MIP <80 cmH₂O for men, <70 cmH₂O for women) will also be assessed.

Exclusion Criteria:

  • tMoCA <18, or diagnosis of neurodegenerative illness at the discretion of principal investigator (except MCI)
  • Current evidence of any major psychiatric disorder including psychosis (at the discretion of principal investigator), bipolar disorder, severe major depression (PHQ-9 > 20)
  • Unstable cardiovascular or pulmonary disease
  • Recent respiratory therapy or major medication changes
  • Self-reported severe untreated or unstable obstructive sleep apnea (OSA)
  • Recent start (within the past month) of CPAP or BiPAP, or recent use of inspiratory muscle training
  • Lung and eardrum injuries
  • Non-English speaking
  • Participants with a pacemaker or other medical implants containing magnets or electronics will be noted and excluded from body composition analyses.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：预防
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：单身的

武器和干预

参与者组/臂
干预/治疗
实验性的：High-Resistance

Participants assigned to the high resistance arm will complete inspiratory muscle strength training (IMST) using a handheld respiratory training device set to 75% of their maximal inspiratory pressure (MIP). Participants will follow the IMST training regimen for the duration of the intervention period, 8-weeks, consisting of 30 breaths per day, completed in a minimum of 5 minutes.
设备：Inspiratory Muscle Strength Training High-Resistance

Investigators will use POWERbreathe® Electronic IMST devices and manually set them to 75% of an individual's IPpeak, depending on their randomization, to the high-resistance IMST group or very low-resistance IMST (sham) group. All participants will complete 30 training breaths per day at home for 8 weeks.
假比较器：Control Group - Low-Resistance

Participants assigned to the low-resistance arm will complete inspiratory muscle strength training (IMST) using a handheld respiratory training device set to 15% of their maximal inspiratory pressure (MIP). Participants will follow the IMST training regimen for the duration of the intervention period, 8-weeks, completing 30 inspiratory breaths per day, with each session lasting a minimum of 5 minutes.
设备：Inspiratory Muscle Strength Training Low-Resistance

Investigators will use POWERbreathe® Electronic IMST devices and manually set them to 15% of an individual's IPpeak, depending on their randomization, to the high-resistance IMST group or very low-resistance IMST (sham) group. All participants will complete 30 training breaths per day at home for 8 weeks.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Change in systolic BP
大体时间：Baseline, 8-weeks

Participants will demonstrate a change in systolic blood pressure (mmHg), assessed as the average of two seated measurements obtained following two consecutive 5-minute rest periods, from baseline to post-intervention.
Baseline, 8-weeks
Change in executive cognitive functioning
大体时间：Baseline, 8 weeks

Participants will demonstrate a change in executive cognitive functioning, assessed using the Fluid Composite Score from the NIH Toolbox Cognition Battery. The Fluid Composite Score is derived from tasks assessing executive function, attention, working memory, episodic memory, and processing speed. Change in executive cognitive functioning will be evaluated as the difference in Fluid Composite Scores from baseline to post-intervention.
Baseline, 8 weeks

次要结果测量

结果测量
措施说明
大体时间
Change from Baseline in Mood Symptoms (Depression) at 8 Weeks
大体时间：Baseline, 8 weeks

Participants will demonstrate a change in depression symptoms, assessed using the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms. Total scores of 5, 10, 15, and 20 represent cut off points for mild, moderate, moderately severe and severe depression. Change in symptoms will be evaluated as the difference in scores from baseline to 8 weeks, with higher scores indicating greater symptom severity.
Baseline, 8 weeks
Change from Baseline in Mood Symptoms (Anxiety) at 8 Weeks
大体时间：Baseline, 8 weeks

Participants will demonstrate a change in anxiety symptoms, assessed using the Geriatric Anxiety Scale-10 (GAS) for anxiety symptoms. Total scores range from 0 to 30, with higher scores indicating greater symptom severity. Change in symptoms will be evaluated as the difference in scores from baseline to 8 weeks, with higher scores indicating greater severity.
Baseline, 8 weeks
Change from Baseline in Sleep Quality at 8 Weeks
大体时间：Baseline, 8 weeks

Participants will demonstrate a change in sleep quality, measured using the Pittsburgh Sleep Quality Index (PSQI) and objective sleep measures collected via actigraphy (Fitbit) devices provided to participants. Change in sleep quality will be evaluated as the difference in PSQI global scores, with higher scores indicating poorer sleep quality, and sleep metrics compiled from actigraphy data from baseline to 8 weeks.
Baseline, 8 weeks
Change from Baseline in Inflammatory Markers (CRP, IL-6, TNF-α) at 8 Weeks
大体时间：Baseline, 8 weeks

Participants will demonstrate a change in inflammatory markers, assessed from fasting blood samples. Serum concentrations of CRP, IL-6, and TNF-α will be measured using standardized laboratory analyses. Change in inflammatory markers will be evaluated from baseline to 8 weeks.
Baseline, 8 weeks
Change from Baseline in Physical Functioning (Grip-Strength) at 8 Weeks
大体时间：Baseline, 8 weeks

Participants will demonstrate a change in physical functioning, assessed using grip strength. Change in physical functioning will be evaluated from baseline to 8 weeks based on performance across these standardized physical function measures. Higher grip strength performance indicate improved physical functioning.
Baseline, 8 weeks
Change from Baseline in Physical Functioning (Gait Speed) at 8 Weeks
大体时间：Baseline, 8 weeks

Participants will demonstrate a change in physical functioning, assessed using gait speed. Change in physical functioning will be evaluated from baseline to 8 weeks based on performance across these standardized physical function measures. Faster gait speed performance indicate improved physical functioning.
Baseline, 8 weeks
Change from Baseline in Physical Functioning (Sit-to-Stand) at 8 Weeks
大体时间：Baseline, 8 weeks

Participants will demonstrate a change in physical functioning, assessed using the sit-to-stand test. Change in physical functioning will be evaluated from baseline to 8 weeks based on performance across these standardized physical function measures. Improved sit-to-stand performance indicate improved physical functioning.
Baseline, 8 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Florida State University

合作者

National Institutes of Health (NIH)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年11月17日

初级完成 (估计的)

2027年2月1日

研究完成 (估计的)

2027年2月1日

研究注册日期

首次提交

2026年1月15日

首先提交符合 QC 标准的

2026年1月15日

首次发布 (实际的)

2026年1月20日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • STUDY00006529

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

IPD 计划说明

Individual participant data will not be shared to protect the privacy and confidentiality of the participants.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅